Sign in

    Ayan Hussein

    Research Analyst at Cantor Fitzgerald

    Ayan Hussein is an Equity Research Associate at Cantor Fitzgerald, specializing in biotech equity research with a strong focus on neuroscience and pharmaceutical companies. He joined Cantor Fitzgerald in New York after earning his PhD in neuroscience in 2021, bringing academic expertise to his equity research coverage. Hussein analyzes and covers a range of biotech firms, leveraging his scientific background to provide detailed industry analysis and investment insights, though specific performance metrics and rankings are not currently available. He holds a PhD in neuroscience, enhancing his credentials as a sector specialist, though there is no public record of FINRA registration or securities licenses.

    Ayan Hussein's questions to RIGEL PHARMACEUTICALS (RIGL) leadership

    Ayan Hussein's questions to RIGEL PHARMACEUTICALS (RIGL) leadership • Q2 2025

    Question

    Ayan Hussein, on behalf of Kristen Kluska, asked for physician feedback on what level of transfusion reduction or independence is considered clinically meaningful for patients with lower-risk MDS.

    Answer

    EVP & Chief Medical Officer Lisa Rojkjaer explained that with current therapies achieving around 40% transfusion independence, a significant unmet need remains for the other 60% of patients. She stated that physicians would welcome any improvement on this rate, also noting that factors like a more convenient oral administration and a better toxicity profile represent opportunities for improvement.

    Ask Fintool Equity Research AI

    Ayan Hussein's questions to X4 Pharmaceuticals (XFOR) leadership

    Ayan Hussein's questions to X4 Pharmaceuticals (XFOR) leadership • Q4 2024

    Question

    Ayan Hussein, on behalf of Kristen Kluska at Cantor Fitzgerald, asked about the patient screening process for the Phase III 4WARD trial and the conversion rate from screening to enrollment.

    Answer

    Paula Ragan (Executive) and Christophe Arbet-Engels (Executive) stated that while specific screening metrics are not being disclosed, site activation has reached 90% of the target. They confirmed that screening is ramping up as expected and the trial is on trajectory for full enrollment in Q3 or Q4 2025.

    Ask Fintool Equity Research AI